Company intelligence / Profile preview

Invirsa

Cincinnati, Ohio, United States

Ownership: Private
Employees: ~11
Development stage: Phase 2

Overview

INV-102 has completed initial testing in dry eye patients (Phases 1 and 2a). The company is advancing to Phase 2 studies for multiple indications and preparing for Phase 3.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

INV-102

Beyond the preview

Go deeper on Invirsa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invirsa.

Explore the full profile